Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
The once-weekly injectable supports weight loss when used alongside a reduced-calorie diet and increased physical activity.
The launch marks a step toward evidence-based, compassionate treatment of obesity as a chronic disease—not a personal failing.
SINGAPORE – Media OutReach Newswire – 12 July 2025 – A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore.
Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health.
The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake1. This mechanism supports weight loss when combined with sustainable lifestyle changes.
ADVERTISEMENT
The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity2–4, a condition associated with more than 200 health complications5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription.
Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, 'Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity'
Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management.
Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said 'With treatments like Wegovy® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes.'
References: Wegovy Singapore Prescribing Information, February 2025 Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508. World Obesity. Retrieved from https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity World Obesity. Retrieved from https://data.worldobesity.org/country/singapore-192/ Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at https://www.cdc.gov/media/releases/2017/p1003-vs-cancer-obesity.html. World Health Organization. (2024). Obesity and overweight.WHO.https://www.who.int/news-room/factsheets/detail/obesity-and-overweight As accessed on 22nd May 2025. Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. https://doi.org/10.3389/fpubh.2023.1082581
Hashtag: #NovoNordisk #Wegovy
The issuer is solely responsible for the content of this announcement.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees.
For more information, visit novonordisk.sg.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
17 hours ago
- Al Etihad
Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban
28 July 2025 14:38 LONDON (REUTERS)A US ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market confidence, investors and analysts Wegovy prescriptions have increased by about 33% since May 22, when a US Food and Drug Administration ban on so-called compounded versions of Wegovy took effect, amounting to 181,200 in the week ended July 18, according to data from IQVIA that was shared with Reuters by industry Wegovy prescriptions have also increased, narrowing the lead for Eli Lilly and Co's Zepbound. In the week ended May 23, U.S. Zepbound prescriptions exceeded Wegovy by nearly 175,000. By July 18, the gap was about 133, signs of a shift come at a critical juncture for Novo. After Wegovy's initial stunning success, investor confidence was rattled when Zepbound and compounders started to slow the drug's then in May, the Danish company cut its full-year sales and earnings forecasts and announced the surprise exit of Chief Executive Lars Fruergaard Jorgensen, citing market challenges and a stock price nearly 60% below its 2024 said at the time he expected the FDA compounding ban to lift sales in the second half of this year. Investors are keen to hear whether that is still likely when the company reports quarterly earnings on August leaves the drugmaker in what Barclays analyst Emily Field called a "show me" phase - no longer buoyed by optimism about a turnaround but under pressure to sales of Wegovy catapulted Novo to become Europe's most valuable listed company, peaking in June 2024 at about 615 billion euros, after the weekly injection became the first highly-effective obesity treatment approved in the US in supply disruptions and gaps in health insurance coverage for Wegovy helped fuel the market for cheaper compounded - or copycat - versions, which are allowed under US law when drugs are in sentiment on Novo soured after the company lost ground to US rival Eli Lilly, which launched Zepbound in late its first full-year forecast downgrade since Wegovy's launch, Novo said in May it expected local-currency sales growth of 13-21%, down from a previous forecast of 16-24%. Operating profit growth is projected at 16-24%, versus 19-27% more of the patients who had turned to compounded drugs is key to meeting those targets. The FDA determined that Wegovy was no longer in shortage in February, leading to the ban on compounded versions. Novo has rolled out new tactics to bring patients back, including a limited-time discount for one month's supply, and secured better coverage from insurer CVS Health.
Zawya
4 days ago
- Zawya
Rainy season increases cholera threat in South Sudan
The ongoing rainy season in South Sudan is slowing cholera response efforts in some locations, raising concerns about further transmission and undermining progress the country has made so far in combating the outbreak. South Sudan experiences heavy rainfall between mid-July and October. The States of Jonglei, Unity, Upper Nile, Northern Bhar el Ghazal, Warrap, parts of Central Equatoria, and others experience seasonal flooding, resulting in massive displacement, and affecting the delivery of basic health services. The rainy season worsens access and sanitation, disrupts the shipment of medical supplies, hinders deployment of rapid response teams, and vaccination impedes efforts, making it difficult to protect communities and save lives. The country declared a cholera outbreak in October 2024, since then, the Ministry of Health with support from World Health Organization (WHO) and other partners, has mounted a comprehensive response, including deployment of rapid response teams, prepositioning medical supplies and coordination efforts across all levels to protect communities and safe lives. This is the longest cholera outbreak in the country's history, since independent in September 2011. As of 30 June 2025, South Sudan has reported a cumulative total of 77 555 suspected cases and 1 401 deaths these cases have been reported from 55 counties, across 9 States and all 3 Administrative areas. A cumulative total of 11 554 tested positive using the rapid diagnostic test kits (RDT), and an additional 424 cases had laboratory isolation of Vibrio Cholera. In response, the country has successfully conducted an oral cholera vaccination campaign, reaching over 6.9 million people in 40 Counties. affected counties, these campaigns have significantly slowed the spread of the outbreak and is estimated to have saved hundreds of lives with a total of 19,987 deaths averted. To support vaccination efforts, South Sudan secured over 8.7 million doses of oral cholera vaccines from the International Coordination Group (ICG) to protect communities, and deployment. the country has applied for additional doses. WHO has played a critical role by training over 2000 health workers and community members on various aspects of the response including case management, risk communication and community engagement, IPC/WASH, vaccination and surveillance. The organization has also supported establishment of 102 oral rehydration points (ORPs), 88 cholera treatment units. (CTUs) and 19 cholera treatment centers (CTCs) through implementing partners, which have significantly reduced fatalities. Over 175 Metric Tons of medical supplies have been distributed across the affected Counties. Additionally, WHO has conducted extensive water quality testing and provided treatment to the affected communities. Several factors have contributed to the outbreak, including high population density, population movement, limited access to water and sanitation facilities, open defecation, and poor hygiene practices, created a highly vulnerable situation that led to imported cases and local transmission. Mr Kereni Gong, Acting Director General, Unity State Ministry of Health highlighted the urgent need for interventions in response to the ongoing flooding, emphasizing the importance of immediate action to save lives of the flooding and call for urgent interventions to save lives 'Unity state is the epicentre of the current cholera outbreak. With support from WHO and other partners The State Ministry of Health managed to bring down the number of cases, but we need more support as we enter the rainy season, during which cases have already begun to rise. We are also aware that floods are coming from the southern part of Unity State which will further worsen the situation' he said Dr Humphrey Karamagi, WHO Representative in South Sudan, underscored the gravity of the situation and express gratitude on the effectiveness of the ongoing cholera response efforts: 'The scale of the current outbreak is unprecedented, the onset of the rainy season poses significant challenge in addition to the prevailing humanitarian crises' said Dr Karamagi 'Under the leadership of the Ministry of Health we have been able to protect the communities by mounting effective response including vaccinating over 7 million people, now Is the time to up our game in strengthening case management, surveillance and coordination to save lives.' Additional funding is required to contain the outbreak, as the rainfall poses the risk of transmission., WHO requires additional funding to bolster current operations by deploying swift response teams to newly identified hotspots, maintaining essential health services for affected communities, and procuring, shipping, and distributing more emergency supplies to support the ongoing response. Distributed by APO Group on behalf of World Health Organization (WHO) - South Sudan.
Zawya
4 days ago
- Zawya
The World Health Organization (WHO) mobilizes digital influencers to combat diseases in Angola
The World Health Organization (WHO) is betting on an innovative approach to stop preventable diseases: engaging digital influencers to directly convey prevention messages to the public through social media. This strategy comes in the context of the cholera outbreak that has been affecting the country since January 2025, with 27,609 cases and 769 deaths recorded in 18 provinces. In addition to containment actions on the ground, the WHO has recognized the importance of occupying the digital space with life-saving content, especially among young people, where incorrect information often circulates. Between May 15 and July 22, the WHO launched the digital campaign 'Together Against Cholera,' which featured six Angolan influencers: Dr. Aurea de Carvalho, Carla Morais, Xofela, Leocádia Tamara, Maria Correia, and Stela de Carvalho. Six educational videos were produced and shared on Facebook, Instagram, and TikTok, with content focused on hygiene, sanitation, and public health. Monitoring data from the WHO's social media pages show that the impact was significant: the videos exceeded 600,000 views, with an average of 3,353 likes, 100 shares, and 70 comments per post, totaling more than 20,000 interactions. Television presenter Stela de Carvalho, who supported the initiative, highlighted its importance, stating: 'Participating in this campaign was a way to use my voice to save lives.' For her part, influencer Xofela reinforced the social role of social media, emphasizing: 'Campaigns like this show that social media can be used for the common good.' According to João Carlos Domingos, WHO communications assistant in Angola, this approach is increasingly necessary: 'Digital has become the main channel of information for many young people, but it is also where a lot of misinformation circulates. We need to fill that space with content that saves lives.' With the encouraging results of this campaign, the WHO in Angola intends to extend this strategy to other areas of public health, namely the prevention of communicable and non-communicable diseases such as malaria, tuberculosis, measles, and hepatitis. The influencers involved have already expressed interest in continuing to collaborate, reinforcing the idea that digital communication, when well guided, can be a powerful ally of public health. Distributed by APO Group on behalf of World Health Organization (WHO) - Angola.
